Prospective randomized controlled trial of auricular point therapy in the treatment of diabetic patients with anxiety and depressio
- Conditions
- Diabetes mellitus combined with anxiety and depression
- Registration Number
- ITMCTR2100005415
- Lead Sponsor
- Fangshan Hospital Beijing University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) meet the diagnostic criteria for type 2 diabetes. (the patient's cognitive and functional status is relatively complete; excluding serious cardiovascular, brain and kidney complications; glycosylated hemoglobin (HbA1c) < 9.0%; the syndrome differentiation of traditional Chinese medicine is liver depression and phlegm obstruction with stasis syndrome: it is mainly characterized by drinking and eating more, thirst and drinking, chest and rib swelling and tightness, accompanied by insomnia, tinnitus, upset and irritable, restlessness, forgetfulness and other symptoms, light tongue, fat tongue, white and greasy fur, twisted sublingual collaterals and stringed veins.)
(2) The evaluation of the scale indicates patients with mild to moderate anxiety and / or depression. (for patients with anxiety or depression with a scale score of 5-19, the course of anxiety and / or depression is less than 5 years)
(3) Age 30-75 years old.
(4) The subjects or their families agreed and signed the informed consent form.
(1) Ear skin infection and other factors affect the operator of ear point comprehensive therapy.
(2) Complicated with more serious primary diseases of other organs or systems.
(3) Unable to cooperate with the operator of auricular point comprehensive therapy.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement rate of insomnia symptoms;
- Secondary Outcome Measures
Name Time Method Fasting blood glucose;Blood glucose 2 hours after meal;Traditional Chinese Medicine symptom score;Time within glucose target range;SF-36;HbA1c;PHQ-9;GAD-7;